80-160 mg two to three times
1 mg slowly IV, repeat after 5-10
minutes if required.
Chronic stable & unstable
angina at rest including vasospastic angina. Long-term therapy after
myocardial infarction; prophylaxis & treatment of supraventricular
40 mg drag or 40 mg drag two to
four times daily. In oral long-term therapy, max : 480 mg.
CV shock, complicated acute
myocardial infarction (bradycardia, marked hypotension, left ventricular
failure); severe conduction disorders ( 2nd or 3rd degree AV block, SA
block), sick-sinus syndrome ( bardycardia-tachycardia syndrome).
1st degree AV block, bradycardia
< 50beats/mins, hypotension < 90 mmHg systolic pressure, atrial
fibrillation/flutter & simultaneous pre-excitation syndrome eg WPW syndrome
( risk of inducing ventricular tachycardia), heart failure ( compensation
with cardiac glycosides). May impair ability to drive or operate machinery.
Nausea, vertigo or dizziness,
headache, flushing, fatigue, nervousness, ankle edema, erythromelalgia,
Myalgia, arthralgia; allergic
skin reactions; gynecomastia, reversible increase in transaminases
&/or alkaline phosphatase; gingival hyperplasia.
Cardiovascular effects enhanced
by β-blockers, antiarrhythmics or inhalation anesthetic. May intensify
BP-lowering effect of other antihypertensives. Rise in digoxin plasma levels
when used with verapamil. Potentiate neurotoxic side effects of
carbamazepine. Attenuate enhanced neurotoxicity of lithium. Increases plasma
level of cyclosporin & theophylline. Effects attenuated by rifampicin.
Effect of muscle relaxants may be potentiated.
Drag 40 mg x 100's, 500's.
80 mg x 250's.
Retard drag 120 mg x 20's.
240 mg x 20's.
Amploules 5 mg x 2 mL x